180 related articles for article (PubMed ID: 38520605)
1. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
Reuss JE; Rosner S; Levy BP
Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
[TBL] [Abstract][Full Text] [Related]
2. Up to the Herculean Task of Tackling Cancer Therapy Resistance.
Papavassiliou KA; Papavassiliou AG
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791904
[TBL] [Abstract][Full Text] [Related]
3. Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
Chen X; Zeng C
Curr Treat Options Oncol; 2024 Apr; 25(4):556-584. PubMed ID: 38520605
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
Abuhelwa Z; Alloghbi A; Nagasaka M
Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
[TBL] [Abstract][Full Text] [Related]
5. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Verma S; Breadner D; Raphael J
Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
[TBL] [Abstract][Full Text] [Related]
6. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
Reuss JE; Gosa L; Liu SV
Clin Lung Cancer; 2021 Nov; 22(6):483-499. PubMed ID: 34420859
[TBL] [Abstract][Full Text] [Related]
7. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C; Mahjoubi L; Gazzah A; Barlesi F
Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.
Marks JA; Wilgucki M; Liu SV; Reuss JE
Curr Oncol Rep; 2022 Dec; 24(12):1829-1841. PubMed ID: 36197593
[TBL] [Abstract][Full Text] [Related]
9. The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
Lefebvre AM; Adam J; Nicolazzi C; Larois C; Attenot F; Falda-Buscaiot F; Dib C; Masson N; Ternès N; Bauchet AL; Demers B; Chadjaa M; Sidhu S; Combeau C; Soria JC; Scoazec JY; Naimi S; Angevin E; Chiron M; Henry C
Lung Cancer; 2023 Oct; 184():107356. PubMed ID: 37660479
[TBL] [Abstract][Full Text] [Related]
10. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations.
D'Arienzo A; Verrazzo A; Pagliuca M; Napolitano F; Parola S; Viggiani M; Caputo R; Puglisi F; Giuliano M; Del Mastro L; Arpino G; De Laurentiis M; Montemurro F
EClinicalMedicine; 2023 Aug; 62():102113. PubMed ID: 37554126
[TBL] [Abstract][Full Text] [Related]
11. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
[TBL] [Abstract][Full Text] [Related]
12. Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy.
Domínguez-Llamas S; Caro-Magdaleno M; Mataix-Albert B; Avilés-Prieto J; Romero-Barranca I; Rodríguez-de-la-Rúa E
Clin Transl Oncol; 2023 Nov; 25(11):3086-3100. PubMed ID: 37454027
[TBL] [Abstract][Full Text] [Related]
13. Antibody-drug conjugates come of age in oncology.
Dumontet C; Reichert JM; Senter PD; Lambert JM; Beck A
Nat Rev Drug Discov; 2023 Aug; 22(8):641-661. PubMed ID: 37308581
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
